Pancreatic Cancer Research

ResearcherUniversity of PalermoActive in the last 2 years

Patrizia Diana

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4883-2004; OpenAlex author ID A5052325016. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 5 papers · 2022: 1 paper · 2023: 3 papers · 2024: 4 papers · 2025: 3 papers · 2026: 1 paper

Papers 22

  1. 3-amino-1,2,4-triazine scaffolds as next-generation PDK inhibitors: Design, mechanistic insights, and efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejmech.2026.119202↗
  2. Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models. Last author DOI 10.1002/cmdc.202500448↗
  3. Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer activity in pancreatic c… Co-author DOI 10.1016/j.bioorg.2024.107995↗
  4. New Marine-Inspired Oxadiazole Derivatives for Use Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/md23080327↗
  5. Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer activity in pancreatic cancer models. Co-author DOI 10.1016/j.bioorg.2024.107959↗
  6. Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: synthesis, … Co-author DOI 10.1080/1061186x.2024.2385557↗
  7. Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.4155/fmc-2023-0234↗
  8. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target. Co-author DOI 10.7150/ijbs.92671↗
  9. Discovery of the 3-Amino-1,2,4-triazine-Based Library as Selective PDK1 Inhibitors with Therapeutic Potential in Highly Aggressive Pancreatic Ductal Adenocarci… Last author DOI 10.3390/ijms24043679↗
  10. Structural Manipulations of Marine Natural Products Inspire a New Library of 3-Amino-1,2,4-Triazine PDK Inhibitors Endowed with Antitumor Activity in Pancreati… Last author DOI 10.3390/md21050288↗
  11. 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Nortopsentin Derivatives against Pancreatic Ductal Adenocarcinoma: Synthesis, Cytotoxic Activity, and Inhibition of CDK1. Co-author DOI 10.3390/md21070412↗
  12. Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15592294.2021.1916697↗
  13. 1,2,4-Oxadiazole Topsentin Analogs with Antiproliferative Activity against Pancreatic Cancer Cells, Targeting GSK3β Kinase. Last author DOI 10.1002/cmdc.202000752↗
  14. GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.drup.2021.100779↗
  15. SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance. Co-author DOI 10.20517/cdr.2021.61↗
  16. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Last author DOI 10.3390/cancers13174389↗
  17. A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells. Co-author DOI 10.3390/molecules27010019↗
  18. Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells. Last author DOI 10.1016/j.ejmech.2020.112088↗
  19. 3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/molecules25020329↗
  20. Pharmacogenetics of treatments for pancreatic cancer. Co-author DOI 10.1080/17425255.2019.1620731↗
  21. Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivative… Co-author DOI 10.21873/anticanres.13509↗
  22. 2-Triazenoazaindoles: α novel class of triazenes inducing transcriptional down-regulation of EGFR and HER-2 in human pancreatic cancer cells. Co-author DOI 10.3892/ijo.2011.1272↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniela Carbone · 19 shared papers, 2019–2026 · strength 3.33
  2. Elisa Giovannetti · 18 shared papers, 2019–2025 · strength 2.97
  3. Barbara Parrino · 17 shared papers, 2019–2026 · strength 2.97
  4. Camilla Pecoraro · 15 shared papers, 2021–2026 · strength 2.86
  5. Stella Cascioferro · 16 shared papers, 2019–2025 · strength 2.58
  6. Godefridus J. Peters · 10 shared papers, 2019–2025 · strength 1.40
  7. Geng Xu · 5 shared papers, 2023–2025 · strength 1.09
  8. Fabio Scianò · 4 shared papers, 2024–2025 · strength 0.90
  9. Juan Deng · 2 shared papers, 2024–2025 · strength 0.47
  10. Btissame El Hassouni · 4 shared papers, 2019–2024 · strength 0.47
  11. Giovanna Li Petri · 4 shared papers, 2019–2020 · strength 0.39
  12. I Gede Putu Supadmanaba · 2 shared papers, 2022–2024 · strength 0.33
  13. Cecilia Bergonzini · 2 shared papers, 2020–2024 · strength 0.29
  14. Ornella Randazzo · 2 shared papers, 2021–2022 · strength 0.28
  15. Amir Avan · 2 shared papers, 2021 · strength 0.27
  16. Mahrou Vahabi · 1 shared paper, 2025 · strength 0.27
  17. Giulia Lencioni · 1 shared paper, 2025 · strength 0.27
  18. Niccola Funel · 2 shared papers, 2020 · strength 0.20
  19. Annalisa Comandatore · 1 shared paper, 2024 · strength 0.18
  20. Amir Avan · 1 shared paper, 2024 · strength 0.18
  21. Giulia Mantini · 1 shared paper, 2024 · strength 0.18
  22. Rocco Sciarrillo · 1 shared paper, 2024 · strength 0.18
  23. Luca Morelli · 1 shared paper, 2024 · strength 0.18
  24. Mjriam Capula · 1 shared paper, 2022 · strength 0.16
  25. Rosa Wijnen · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.